eFFECTOR Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- eFFECTOR Therapeutics's estimated annual revenue is currently $6.4M per year.
- eFFECTOR Therapeutics's estimated revenue per employee is $155,000
Employee Data
- eFFECTOR Therapeutics has 41 Employees.
- eFFECTOR Therapeutics grew their employee count by 3% last year.
eFFECTOR Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Financial Officer | Reveal Email/Phone |
2 | Co-Founder | Reveal Email/Phone |
3 | Director Development Operations | Reveal Email/Phone |
4 | Senior Manager Financial Reporting | Reveal Email/Phone |
eFFECTOR Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.4M | 70 | -8% | $53M | N/A |
#2 | $32.4M | 167 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.8M | 18 | 13% | N/A | N/A |
#5 | $0.8M | 5 | -50% | N/A | N/A |
#6 | $0.8M | 10 | 0% | N/A | N/A |
#7 | $14M | 90 | -12% | N/A | N/A |
#8 | $0.4M | 336 | 10% | $236.7M | N/A |
#9 | $4.8M | 62 | -74% | $160M | N/A |
#10 | $3.7M | 24 | -8% | N/A | N/A |
What Is eFFECTOR Therapeutics?
eFFECTOR Therapeutics is a clinical-stage biopharmaceutical company focused on pioneering the discovery and development of a new class of oncology drugs known as selective translation regulators (STRs). Translation is the process in cells whereby the synthesis of proteins is directed by information contained in genetic sequences. Each of eFFECTOR's product candidates is designed to act on a single protein that regulates, in a coordinated manner, the expression of multiple functionally related proteins that together drive important biological processes such as immune evasion, stress and inflammatory responses, as well as cell proliferation.
keywords:N/A
N/A
Total Funding
41
Number of Employees
$6.4M
Revenue (est)
3%
Employee Growth %
N/A
Valuation
N/A
Accelerator
eFFECTOR Therapeutics News
Analysts expect eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR Get Rating) to report earnings of ($0.32) per share for the current fiscal...
eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR) Receives Consensus Recommendation of Buy from Analysts. Posted by admin on Apr 20th, 2022.
eFFECTOR is a clinical-stage biopharmaceutical company focused on pioneering the development of a new class of oncology drugs referred to as...
Other Companies in San Diego
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $8.9M | 41 | N/A | N/A |
#2 | $4.8M | 41 | 0% | N/A |
#3 | $3.2M | 41 | 28% | $43M |
#4 | $8.2M | 41 | 11% | N/A |
#5 | $3.9M | 41 | 11% | N/A |